Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNXNASDAQ:DCTHOTCMKTS:EDTXFNASDAQ:EMBC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$17.20+12.0%$12.38$8.89▼$24.50$745.72MN/A485,303 shs1.23 million shsDCTHDelcath Systems$16.07-5.8%$13.30$6.33▼$18.23$559.65M0.72376,746 shs576,064 shsEDTXFSpectral Medical$0.620.0%$0.57$0.32▼$0.65$175.72M0.215,957 shs1,800 shsEMBCEmbecta$10.62+1.6%$11.90$10.27▼$21.48$620.67M1.24465,148 shs830,947 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics0.00%+19.20%+45.39%-18.02%+1,719,999,900.00%DCTHDelcath Systems0.00%-0.25%+29.60%+20.37%+127.94%EDTXFSpectral Medical0.00%+0.37%+7.73%+17.88%+78.04%EMBCEmbecta0.00%-0.93%-16.58%-17.48%-14.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBNXBeta BionicsN/AN/AN/AN/AN/AN/AN/AN/ADCTHDelcath Systems3.5209 of 5 stars3.55.00.00.03.32.50.6EDTXFSpectral Medical0.0635 of 5 stars0.03.00.00.00.00.00.0EMBCEmbecta4.8359 of 5 stars3.25.03.30.02.53.33.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.73Moderate Buy$23.1334.45% UpsideDCTHDelcath Systems 3.00Buy$24.0049.35% UpsideEDTXFSpectral Medical 0.00N/AN/AN/AEMBCEmbecta 2.33Hold$19.3382.05% UpsideCurrent Analyst Ratings BreakdownLatest EDTXF, BBNX, EMBC, and DCTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.005/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/7/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $24.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$69.83M10.68N/AN/AN/A∞DCTHDelcath Systems$53.85M10.39N/AN/A$0.72 per share22.32EDTXFSpectral Medical$1.18M148.91N/AN/A($0.04) per share-15.41EMBCEmbecta$1.08B0.57$2.46 per share4.32($13.23) per share-0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta BionicsN/AN/A0.00∞N/AN/AN/AN/AN/ADCTHDelcath Systems-$47.68M-$0.50N/AN/AN/A-150.70%-338.16%-104.02%8/4/2025 (Estimated)EDTXFSpectral Medical-$11.60M-$0.07N/A∞N/A-1,245.87%N/A-351.89%8/7/2025 (Estimated)EMBCEmbecta$78.30M$0.9010.623.460.785.25%-19.22%11.92%8/8/2025 (Estimated)Latest EDTXF, BBNX, EMBC, and DCTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025EDTXFSpectral MedicalN/A-$0.03N/A-$0.03N/A$0.40 million5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 million5/6/2025Q1 2025BBNXBeta Bionics-$0.51-$0.52-$0.01-$0.93N/AN/A3/25/2025Q4 2024BBNXBeta Bionics-$0.42-$1.82-$1.40-$2.72$20.01 million$20.44 million3/6/2025Q4 2024DCTHDelcath Systems-$0.10-$0.11-$0.01-$0.11$14.96 million$15.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/AEDTXFSpectral MedicalN/AN/AN/AN/AN/AEMBCEmbecta$0.605.65%N/A66.67%N/ALatest EDTXF, BBNX, EMBC, and DCTH DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/AN/AN/ADCTHDelcath SystemsN/A1.341.03EDTXFSpectral MedicalN/A0.220.21EMBCEmbectaN/A2.241.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/ADCTHDelcath Systems61.12%EDTXFSpectral MedicalN/AEMBCEmbecta93.83%Insider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/ADCTHDelcath Systems17.40%EDTXFSpectral Medical1.50%EMBCEmbecta0.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.36 millionN/AN/ADCTHDelcath Systems6034.83 million26.24 millionOptionableEDTXFSpectral Medical29285.12 million280.48 millionNot OptionableEMBCEmbecta1,90058.44 million57.89 millionOptionableEDTXF, BBNX, EMBC, and DCTH HeadlinesRecent News About These CompaniesEmbecta Corp. (NASDAQ:EMBC) Short Interest Down 20.1% in MayJune 2 at 4:05 AM | marketbeat.comNuveen Asset Management LLC Decreases Position in Embecta Corp. (NASDAQ:EMBC)June 2 at 3:58 AM | marketbeat.comEmbecta (NASDAQ:EMBC) Trading Down 4.9% - Here's WhyMay 30 at 4:31 PM | marketbeat.comAmeriprise Financial Inc. Reduces Position in Embecta Corp. (NASDAQ:EMBC)May 29, 2025 | marketbeat.comEmbecta (NASDAQ:EMBC) Trading 6.3% Higher - Time to Buy?May 28, 2025 | marketbeat.comembecta to Participate in Investor EventsMay 27, 2025 | globenewswire.comJane Street Group LLC Has $846,000 Stock Position in Embecta Corp. (NASDAQ:EMBC)May 26, 2025 | marketbeat.comMizuho Cuts Embecta (NASDAQ:EMBC) Price Target to $13.00May 26, 2025 | americanbankingnews.comEmbecta (NASDAQ:EMBC) Price Target Lowered to $13.00 at MizuhoMay 25, 2025 | marketbeat.comIndependent Non-Executive Chairman of Embecta Picks Up 13% More StockMay 25, 2025 | finance.yahoo.comDavid F. Melcher Purchases 10,000 Shares of Embecta Corp. (NASDAQ:EMBC) StockMay 24, 2025 | insidertrades.comOMERS ADMINISTRATION Corp Trims Stock Position in Embecta Corp. (NASDAQ:EMBC)May 23, 2025 | marketbeat.comEmbecta eyes shift from insulin delivery to broader medical supplies focusMay 22, 2025 | drugdeliverybusiness.comembecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor DayMay 22, 2025 | globenewswire.comJacobs Levy Equity Management Inc. Lowers Position in Embecta Corp. (NASDAQ:EMBC)May 18, 2025 | marketbeat.comEmbecta Corp. (NASDAQ:EMBC) Stock Holdings Increased by Northern Trust CorpMay 18, 2025 | marketbeat.comEmbecta: Not Nearly As Cheap As The 4x Forward P/E Ratio Would ImplyMay 15, 2025 | seekingalpha.comMeros Investment Management LP Purchases 57,312 Shares of Embecta Corp. (NASDAQ:EMBC)May 15, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Trims Position in Embecta Corp. (NASDAQ:EMBC)May 15, 2025 | marketbeat.comEmbecta (NASDAQ:EMBC) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPSMay 12, 2025 | marketbeat.comAQR Capital Management LLC Trims Stock Position in Embecta Corp. (NASDAQ:EMBC)May 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEDTXF, BBNX, EMBC, and DCTH Company DescriptionsBeta Bionics NASDAQ:BBNX$17.20 +1.84 (+11.98%) As of 05/30/2025 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Delcath Systems NASDAQ:DCTH$16.07 -0.99 (-5.80%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$16.42 +0.35 (+2.17%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Spectral Medical OTCMKTS:EDTXF$0.62 0.00 (-0.03%) As of 05/30/2025 02:41 PM EasternSpectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.Embecta NASDAQ:EMBC$10.62 +0.17 (+1.63%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$10.54 -0.07 (-0.71%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
